

# Isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease: Updated results from an ongoing Phase 1/2 study (STAAR)


**Robert J. Hopkin<sup>1</sup>**

<sup>1</sup>Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

February 7, 2024

1

— ST-920 employs a recombinant AAV2/6 vector with human GLA cDNA for continuous, liver-specific  $\alpha$ -Gal-A expression



## Advantages

- Convenient one-time administration
- Potential to eliminate ERT infusions
- Durable efficacy
- Low immunogenicity
- No prophylaxis with steroids or other immunomodulating agents required

# STAAR Phase 1/2 clinical study overview

Global, multicenter, open-label, single dose, dose ranging study (ST-920-201, NCT04046224)

## Eligibility


- Age  $\geq 18$  with symptomatic Fabry disease
  - ERT-naïve or pseudo-naïve (no ERT in prior 6 months)
  - On ERT
- eGFR  $\geq 40$  mL/min/1.73m<sup>2</sup>
- No neutralizing antibodies to AAV6

## Primary objective

- Safety and tolerability of ST-920

## Other objectives - Evaluate

- $\alpha$ -Gal A activity and change in plasma lyso-Gb3
- Impact on ERT administration
- Renal and cardiac function (+ renal Gb3 inclusions)
- Patient-reported outcomes and QoL scores
- Immunogenicity



## Baseline characteristics: Dose escalation and dose expansion phases

	Dose escalation (n=9)	Dose expansion (n=15)	All (n=24)
<b>Age, median (range)</b>	42 (22-50)	45 (21-67)	44 (21-67)
<b>Sex (M:F)</b>	9:0	6:9	15:9
<b>ERT status (n,%):</b>			
• Naïve	2 (22%)	4 (27%)	6 (25%)
• Pseudo-naïve	2 (22%)	3 (20%)	5 (21%)
• On ERT	5 (56%)	8 (53%)	13 (54%)
<b>Baseline Fabry symptoms (n,%):</b>			
• Cornea verticillata	4 (44%)	8 (53%)	12 (50%)
• Acroparesthesia	3 (33%)	3 (20%)	6 (25%)
• Anhidrosis	1 (11%)	2 (13%)	3 (13%)
• Angiokeratoma	2 (22%)	7 (47%)	9 (38%)
<b>eGFR<sub>CKD-EPI</sub> category, n (%)</b>			
• >90 ml/min/1.73 m <sup>2</sup>	5 (56%)	9 (60%)	14 (58%)
• 60-90 ml/min/1.73 m <sup>2</sup>	3 (33%)	3 (20%)	6 (25%)
• 40-<60 ml/min/1.73 m <sup>2</sup>	1 (11%)	3 (20%)	4 (17%)

Data cut-off date: 19 September 2023

eGFR, estimated glomerular filtration rate (mL/min/1.73m<sup>2</sup>); ERT, enzyme replacement therapy

# ST-920 is generally well tolerated with a favorable safety profile

## Summary of treatment-emergent AEs in >2 subjects

AE by preferred term	Treated subjects (n=24)	
	All grades	Grade 3-4
Pyrexia	15 (63%)	1 (4%) (G3)
Headache	9 (38%)	0
COVID-19	9 (38%)	0
Fatigue	7 (29%)	0
Nasopharyngitis	6 (25%)	0
Diarrhea	4 (17%)	0
Hypotension	4 (17%)	0
Nausea	4 (17%)	0
Arthralgia	3 (13%)	0
Viral infection	3 (13%)	0
Myalgia	3 (13%)	1 (4%) (G3)
Neck pain	3 (13%)	0



Data cut-off date: 19 September 2023

AE, adverse event; ALT, alanine aminotransferase; LFT, liver function test; n, number of subjects with AE; TESAE, treatment-emergent serious adverse event; ULN, upper limit of normal; vg/kg, vector genomes per kilogram of total body weight (as assessed by ddPCR)

- ST-920 was generally well-tolerated with majority of AEs being grade 1-2 in nature, as of the 19 Sep 2023 cut-off date
- 3 subjects (12%) experienced post-infusion hypotension:
  - Grade 2, steroids administered (n=2)
  - Grade 1, saline bolus administered (n=1)
- No LFT elevations requiring steroids
  - Steroids administered for ALT  $\uparrow \geq 2x$  baseline and  $>ULN$ , or  $\uparrow >2x$  baseline  $\times 2$  consecutive values
  - Prophylactic steroids/other immunosuppressive agents were not required prior to dosing
- TESAEs were reported in 4 subjects: left arm pain ( $0.53 \times 10^{13}$  vg/kg); sepsis ( $1.58 \times 10^{13}$  vg/kg); enthesopathy, stroke/ischemic stroke ( $2.63 \times 10^{13}$  vg/kg)
- No AEs led to study discontinuation





# Follow-up for up to 36 months

- Median duration of follow-up: 51.1 weeks (0.9 wk - 36.2 months)
- 13 subjects have  $\geq 12$  months of follow-up
- Supraphysiological levels of  $\alpha$ -Gal A activity were maintained for up to 36.2 months



# Dose-dependent effect on $\alpha$ -Gal A activity in naïve/pseudo-naïve subjects

$2.63 \times 10^{13}$  vg/kg selected for expansion phase



Data cut-off date: 19 September 2023


$\alpha$ -Gal A activity measured using 3-hour reaction time. Normal range determined in healthy males and females. Data points > Study Day 365 are from long-term follow-up study.

$\alpha$ -Gal A, alpha-galactosidase A; vg/kg, vector genomes per kilogram of total body weight (as assessed by ddPCR); ERT, ERT-treated at baseline; N, ERT-naïve; P-N, pseudo-naïve, no ERT in  $\geq 6$  months prior to screening


# ST-920-driven plasma $\alpha$ -Gal A activity and reduction in lyso-Gb3 in ERT naïve/pseudo-naïve subjects receiving $2.63 \times 10^{13}$ vg/kg (n=9)

- Sustained supraphysiological  $\alpha$ -Gal A activity up to nearly 500 days
- Largest reductions in plasma lyso-Gb3 in subjects with highest levels at baseline
- Long-term stabilization of lyso-Gb3 levels


**Large reduction in plasma lyso-Gb3 possible with modest levels of continuous  $\alpha$ -Gal A activity**



**Plasma  $\alpha$ -Gal A activity**



**Plasma lyso-Gb3**



Data cut-off date: 19 September 2023

$\alpha$ -Gal A activity measured using 3-hour reaction time. Normal range determined in healthy males and females. Long Term Follow-up Data: Data points > Study Day 365.



$\alpha$ -Gal A, alpha-galactosidase A; ERT, enzyme replacement therapy; lyso-Gb3, globotriaosylsphingosine; vg/kg, vector genomes per kilogram of total body weight (as assessed by ddPCR)



# All subjects withdrawn from ERT post-ST-920 infusion remain off ERT

- Timing of ERT withdrawal was at the discretion of the investigator, to occur no earlier than 8 weeks post-ST-920 dosing
- All 12 subjects withdrawn from ERT remain off ERT; 11 maintain sustained supraphysiological levels of  $\alpha$ -Gal A activity for up to ~19 months (1 sustained physiological levels) as of the data cut-off
- Plasma lyso-Gb3 levels remained stable following ERT withdrawal for up to 1 year (last study timepoint)

## Plasma $\alpha$ -Gal A and lyso-Gb3 in ERT-treated subjects receiving $2.63 \times 10^{13}$ vg/kg (n=8)



Data cut-off date: 19 September 2023

$\alpha$ -Gal A activity measured using 3-hour reaction time. Normal range determined in healthy males and females.

$\alpha$ -Gal A, alpha-galactosidase A; ERT, enzyme replacement therapy; lyso-Gb3, globotriaosylsphingosine; vg/kg, vector genomes per kilogram of total body weight (as assessed by ddPCR); W, week


# Maintained stability of renal function in subjects with $\geq 12$ m of follow-up

**Mean annualized eGFR slope:**

-0.915 mL/min/1.73m<sup>2</sup> /year  
(95% CI: -4.1, 2.3)

**Median eGFR at baseline:**

96.7 mL/min/ 1.73m<sup>2</sup>



# Significant improvements in disease severity, quality of life and GI symptoms

## FOS-MSSI:

- Mean change from baseline at Month 12 in age-adjusted score: **-3.96** (95% CI: [-7.4,-0.5]), p=0.0269
- 9/13 (69%) improved their total MSSI score from baseline at Month 12
- 4 subjects (1 treatment-naïve) improved their disease category
- Improvements in each of the 4 MSSI sections were observed
- Subjects on ERT at baseline then withdrawn from ERT:
  - 6/8 (75%) improved scores (by -3.5 to -14 points)
  - 3/8 (38%) improved their disease category

## SF-36: Mean change from baseline at Month 12 in

- General Health score: **+10.5** (95% CI: [2.3, 18.6], p=0.0158)
- Physical Component score: **+4.395** (95% CI: [1.1, 7.7], p=0.0140)

## GSRS (GI Symptom Rating Scale):

- Mean change from baseline at Month 12 = **-0.26**, 95% CI: [-0.5, -0.0], p=0.0226

Subject	ERT at Baseline?	FOS-MSSI category: Baseline	FOS-MSSI category: Week 52
1	ERT	Moderate	Moderate
2	Pseudo-naive	Mild	Mild
3	Pseudo-naive	Moderate	Moderate
4	ERT	Mild	Mild
5	ERT	Moderate	<b>Mild</b>
6	ERT	Moderate	<b>Mild</b>
7	ERT	Severe	<b>Moderate</b>
8	Naive	Moderate	<b>Mild</b>
9	Naive	Moderate	Moderate
10	Pseudo-naive	Moderate	Moderate
11	ERT	Moderate	Moderate
12	ERT	Mild	Mild
13	ERT	Mild	Mild

## Reduction or elimination of antibodies against $\alpha$ -Gal A

	Anti- $\alpha$ -GalA Total Ab titer		Anti- $\alpha$ -GalA NAb titer	
	Baseline	On-study	Baseline	On-study
Subject 1	1280	160	160	Undetectable (W36)
Subject 3	160	Undetectable (W24)	0	-
Subject 4	160	Undetectable (W52)	0	-
Subject 5	10240	1280	320	160
Subject 10	80	Undetectable (W4)	10	-
Subject 13	5120	320	160	10
Subject 16	2560	Undetectable (W36)	40	-

Data cut-off date: 19 September 2023

$\alpha$ -Gal A, alpha-galactosidase A; Ab, antibody; NAb, neutralizing antibody; W, week; (-) denotes NAb testing not done when total Ab titer is 0

- Progressive organ impairment linked to immunogenicity remains an issue with ERT
- 7 subjects had measurable titers of total antibodies (Ab) or neutralizing antibodies (NAb) against  $\alpha$ -Gal A associated with ERT
- After ST-920 treatment, total Ab or NAb titers decreased markedly in all 7 subjects and became undetectable in 5 (71%)
- ST-920 treatment did not induce anti- $\alpha$ -Gal A antibodies in seronegative subjects

## Summary

- ✓ ST-920 gene therapy was well-tolerated with an excellent safety profile in this population of adults with symptomatic Fabry disease:
  - No prophylactic steroids/other immunomodulatory agents administered
  - No LFT elevations requiring steroids
- ✓ Durable efficacy was demonstrated, with supraphysiological levels of  $\alpha$ -Gal A activity maintained for up to 36.2 months
  - Largest plasma lyso-Gb3 reductions seen in naïve/pseudo-naïve subjects with highest baseline values
- ✓ Compared to baseline, the 13 subjects with  $\geq 12$  months of follow-up showed:
  - Renal function remained stable
  - Significant improvement in FOS-MSSI disease severity score, with 38% of subjects on ERT improving in disease severity category
  - Significant improvement in SF-36 QoL and GSRS GI symptom scores
- ✓ All 12 subjects who discontinued ERT remain off ERT for up to 19 months, as of the data cut-off
  - 11/12 maintain sustained supraphysiological  $\alpha$ -Gal A activity (1 with sustained  $\alpha$ -Gal A activity in normal physiologic range)
  - 75% (6/8) had an improved disease severity score at 12 months compared to their baseline severity score on ERT
- ✓ Total or neutralizing  $\alpha$ -Gal A antibodies decreased markedly in 7 subjects and became undetectable in 5 (71%)
- ✓ ***ST-920 has potential as a one-time, durable treatment option for Fabry disease that can improve patient outcomes***

# Acknowledgments

## Investigators:

- **Dr. Robert J. Hopkin**, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, OH
- **Prof. Derralynn Hughes**, Royal Free London Hospital, London, UK
- **Dr. Jaya Ganesh**, The Icahn School of Medicine at Mount Sinai, New York, NY
- **Dr. John Bernat**, University of Iowa Hospitals & Clinics, Iowa City, IA
- **Dr. Ozlem Goker-Alpan**, Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, VA
- **Dr. Kathy Nicholls**, The Royal Melbourne Hospital and The University of Melbourne, Melbourne, Australia
- **Dr. Madeleine Pahl**, University of California, Irvine, CA
- **Dr. Patrick Deegan**, Addenbrooke's Hospital, Cambridge, UK
- **Dr. Chester B. Whitley**, University of Minnesota, Minneapolis, MN
- **Dr. William Wilcox**, Emory University School of Medicine, Atlanta, GA

## Sponsor: Sangamo Therapeutics, Inc.

- Dr. Lisa Rojkjaer
- Dr. Ben Hsu
- Michael Chen
- Liching Cao

We would like to thank the patients, their families, the investigators and their study teams for their participation in this study!